Please assess the completion status of the following clinical trial:

Trial Title: Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Urinary Incontinence for at least 3 months prior to Screening as a result of Neurogenic Detrusor Overactivity due to Spinal Cord Injury or Multiple Sclerosis.~* Subjects with Spinal Cord Injury must have a stable neurological injury at T1 level or below which occurred at least 6 months prior to Screening.~* Subjects with Multiple Sclerosis must be clinically stable in the investigator's opinion, with no exacerbation (relapse) of MS for at least 3 months prior to Screening.~* Subjects must have had an inadequate response after at least 4 weeks of oral medications used in the treatment of NDO (e.g. anticholinergics, beta-3 agonists) and/or have intolerable side-effects.~* Routinely performing Clean Intermittent Catheterization (CIC) to ensure adequate bladder emptying.~* An average of at least two episodes per day of Urinary Incontinence recorded on the screening bladder diary.~Key Exclusion Criteria:~* Any current condition (other than NDO) that may impact on bladder function.~* Previous or current, tumour or malignancy affecting the spinal column or spinal cord, or any other unstable cause of SCI.~* Any condition that will prevent cystoscopic treatment administration or CIC usage, e.g. urethral strictures.~* Current indwelling bladder catheter, or removal of indwelling bladder catheter less than 4 weeks prior to Screening.~* BTX-A treatment within 9 months prior to Screening for any urological condition (e.g. detrusor or urethral sphincter treatments).~* Any neuromodulation/electrostimulation usage for urinary symptoms/incontinence within 4 weeks prior to Screening. Any implanted neuromodulation device must be switched off at least 4 weeks prior to Screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 600 U Dysport® Group (Type: EXPERIMENTAL): None
- 600 U Dysport® Placebo Group (Type: PLACEBO_COMPARATOR): None
- 800 U Dysport® Group (Type: EXPERIMENTAL): None
- 800 U Dysport® Placebo Group (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).